Taxonomic inventory and distributions of Chenopodiaceae (Amaranthaceae s.l.) in Orenburg Region, Russia.

Background: Orenburg Region is located in the South Urals, mostly in the steppe zone and is characterised by various landscapes suitable for many Chenopodiaceae. The species of Chenopodiaceae are present in all major plant communities (saline vegetation, steppes, on limestone, chalk and sand, and as degraded or ruderal communities). In the steppe zone, many native subshrubby species (, , ) playing a crucial role in semi-deserts (known as southern steppes in the recent Russian literature) located southwards of Orenburg Region are locally found, and several annuals (, spp.

Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.

Background And Aims: Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited condition characterized by elevated plasma low-density lipoprotein-cholesterol (LDL-C) levels, severe, accelerated atherosclerosis and premature coronary heart disease. We evaluated cardiovascular complications in HoFH patients over extended follow-up and investigated their association with changes in cholesterol over time, as well as total cholesterol burden.

Methods: In this retrospective single-centre study, 53 patients (baseline mean ± standard deviation [SD], total cholesterol 15.

Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors.

Background: We evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk.

Methods: The distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls.

Results: No significant modification appeared in HDL distribution between the two arms of statins for the HIV-1-infected individuals.

Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.

Objective: HIV infection is associated with an atherogenic lipoprotein profile, and ritonavir-boosted protease inhibitors exacerbate this phenotype. We evaluated the effect of 45 days of rosuvastatin versus pravastatin on the low-density lipoprotein (LDL) size and the distribution of LDL subfractions in HIV-1 patients receiving boosted protease inhibitors with elevated LDL levels.

Design: Substudy of the randomized double-blind multicentre ANRS 126 VIHstatine trial.

Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients.

Background: Lipid disorders are frequent in HIV-1-infected patients taking combination antiretroviral therapy (cART) that includes protease inhibitors (PIs). The presence of small dense low-density lipoprotein particles might be an important predictive marker of cardiovascular disease in this setting. This cross-sectional substudy of the ANRS 126 trial was designed to identify variables influencing LDL diameter.

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.

Background: HIV infection and its treatment with protease inhibitors, especially when boosted with ritonavir, can cause lipid disorders. Statins, with the exception of fluvastatin, pravastatin and rosuvastatin, interact with protease inhibitor metabolism via CYP450. Pravastatin is recommended for patients with protease inhibitor-associated dyslipidemia.